MBUU Stock News 20.80 05/13/2014 11:37:38 Malibu Boats Inc.

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Malibu Boats Inc. (MBUU) 20.80 $MBUU

Pool Corp. Set to Return Shareholder Wealth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon May 12, 5:30PM CDT
Pool Corp. (POOL) recently authorized an additional stock repurchase program and increased its dividend.

Malibu Boats, Inc. Announces Third Quarter Fiscal 2014 Results
GlobeNewswire - Wed May 07, 3:46PM CDT
Net Sales Increased 6.9% to $50.3 million

Higher Gun Sales Propel Strum, Roger & Co Earnings Beat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 10:10AM CDT
Sturm, Ruger & Company, Inc. (RGR) reported first quarter 2014 earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.11 by 9.9%.

Malibu Boats, Inc. Announces Earnings Release Date and Conference Call Information for Third Quarter Fiscal 2014 Financial Results
GlobeNewswire - Tue Apr 29, 9:29AM CDT
Malibu Boats, Inc. (Nasdaq:MBUU) announced today that it will release its financial results for the third quarter of fiscal year 2014 on Wednesday, May 7, 2014 after the markets close. Following the release, the company's management will host a conference call to discuss the results at 4:30 p.m. Eastern Time on the same day.

Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:

How Malibu Boats (MBUU) Stock Stands Out in a Strong Industry - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 08, 7:50AM CDT
Malibu Boats might be an intriguing choice for investors right now as it is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.

Earnings Estimates Moving Higher for Malibu Boats (MBUU): Time to Buy? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:37AM CDT
Malibu Boats has decent short-term momentum and is seeing solid activity on the earnings estimate revision front. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Malibu Boats could be a solid choice for investors.

The NASDAQ Stock Market Leads U.S. Exchanges for IPOs in Q1 2014
GlobeNewswire - Thu Mar 27, 7:50AM CDT
74 New U.S. Listings Including 45 IPOs

Why Malibu Boats Inc. Is a Cut Above Other Boat Builders
Mark Lin, The Motley Fool - Motley Fool - Wed Mar 19, 12:00PM CDT
Source: Malibu Boats The National Marine Manufacturers Association values the U.S. market for powerboats at $4 billion, and recent trends point to strong growth prospects. While new powerboats accounted for 25% of powerboats sold prior to the...

Malibu Boats, Inc. Announces Second Quarter Fiscal 2014 Results
GlobeNewswire - Fri Mar 07, 6:00AM CST
Second Quarter Net Sales Increased 16.2% to $43.9 million

Malibu Boats, Inc. Announces Earnings Release Date and Conference Call Information for Fiscal Second Quarter 2014 Financial Results and Participation in the Raymond James 35th Annual Institutional Investors Conference
GlobeNewswire - Thu Feb 27, 3:51PM CST
Malibu Boats, Inc. (Nasdaq:MBUU) announced today that it will release its financial results for the second quarter of fiscal year 2014 before the open of regular market trading on Friday, March 7, 2014. Following the release, the company's management will host a conference call to discuss the results at 8:30 a.m. Eastern Time on the same day.

Form 3: Initial Filing for Malibu Boats Inc (MBUU)
Vickers Stock Research - Tue Feb 11, 4:02AM CST
Fourth quarter sales revenue totalled EUR725 million (up 20%), making for total sales revenue of EUR2,792 million over 12 months (up 32%). At constant perimeter consolidated sales revenue is up 13%.

IPO roundup: 6 companies go public Friday
By The Associated Press - AP - Fri Jan 31, 5:32PM CST
Six companies made their stock market debuts Friday as the IPO market revs up in 2014. Last year the market for initial public offerings boomed as stock markets rose, with major debuts from hotel owner Hilton Worldwide Holdings Inc., which raised $2.35 billion, and online messaging service Twitter Inc., which raised $2.1 billion.

Malibu Boats, Inc. Announces Pricing of Initial Public Offering
GlobeNewswire - Thu Jan 30, 7:12PM CST
Malibu Boats, Inc. today announced the pricing of its initial public offering of 7,142,858 shares of Class A Common Stock at a price of $14.00 per share. Malibu Boats, Inc. is offering 6,743,744 shares and the selling stockholders are offering 399,114 shares. In connection with the offering, Malibu Boats, Inc. and the selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 1,071,429 shares of Class A Common Stock to cover over-allotments, if any. The shares will be listed on the Nasdaq Global Select Market beginning on January 31, 2014 under the ticker symbol "MBUU." The offering is expected to close on February 5, 2014.

Pacific Coast Marine Windshield Wins Appeal in Patent Infringement Suit
Business Wire - Fri Jan 10, 1:14PM CST
Pacific Coast Marine Windshields (PCMW), a leading manufacturer of innovative windshield designs for recreational boats, announced today that it has prevailed before the Federal Circuit Court of Appeals in its patent infringement suit against Malibu Boats and other defendants.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

ASTS Faces Class Action; Investors Beware of Pitfalls

Updated Category News Views 183

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

Continue Reading
Moon Base Ambitions: Impulse Space Wins Key NASA Contracts

Updated Category News Views 742

NASA's Vision and Impulse's New Role Ever think you'd see a company like Impulse Space set to play a starring role in humanity's return to the lunar surface? Well, strap in because this isn't just a pipe dream anymore. NASA's bold plan to establish a Moon Base has taken a tangible step forward with Impulse winning two hefty task orders. This ain't just peanuts—this duo...

Continue Reading
D-Wave's Legal Trouble: Securities Fraud Suit Looms

Updated Category News Views 235

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Continue Reading
Fibocom LTE Modules Test Drive Satellite Connectivity

Updated Category News Views 63

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

Continue Reading
MWC26 Doha: Bridging Standards for MENA's Future

Updated Category News Views 437

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Continue Reading
JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Updated Category News Views 209

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

Continue Reading
Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Updated Category News Views 256

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Continue Reading
Allergan Aesthetics Study Shows Rising Patient Satisfaction

Updated Category News Views 222

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

Continue Reading
Intelligent Communication Forum Eyes Global Ecosystem Shift

Updated Category News Views 490

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...

Continue Reading
Novo's Semaglutide Shows Promise in MASH Study

Updated Category News Views 221

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Continue Reading

Top 5 Most Recently Viewed Articles

Marina Genova Joins SEA Index to Promote Sustainable Yachting

Updated Category News Views 173

Marina Genova Enters SEA Index as an Institutional Member Recently, the Superyacht Eco Association – SEA Index welcomed Marina Genova, a prominent destination for yachting in the Mediterranean, as an Institutional Member. This collaboration signifies a crucial step in the yachting community's commitment to integrating environmental sustainability into its operations....

Continue Reading
Warren Buffett’s Top 2025 Stock Picks You Need to Know

Updated Category News Views 2610

Warren Buffett’s Strategic Stock Investments for 2025 Warren Buffett, the Oracle of Omaha, is known for his keen investment strategies and ability to recognize value in both good and bad market conditions. In the current volatile landscape, his portfolio continues to evolve, with some old favorites and new bets that show his forward-thinking approach. As we look ahead...

Continue Reading
Graves' Ophthalmopathy Market Surges with New Therapies

Updated Category News Views 50

Unexpected Growth in Graves' Ophthalmopathy Market Over the next decade, we're seeing the Graves' ophthalmopathy market gearing up for some serious growth, clocking in at a hefty compound annual growth rate of 9%. A good chunk of this is thanks to Viridian's newest player, LUMVOA, getting the green light, sending competitors scrambling and pushing innovation into...

Continue Reading
Tris Pharma Launches ONYDA XR: A New ADHD Liquid Solution

Updated Category News Views 210

So back in 2024, Tris Pharma rolled out ONYDA™ XR—this liquid medication aimed at tackling ADHD in kids six and older. It was billed as a game changer, especially since the FDA gave it the green light. The desks were buzzing about this first-of-its-kind non-stimulant therapy, positioning it like a golden ticket for parents tired of conventional stimulants that might...

Continue Reading
JPMorgan Updates Price Target for W. P. Carey to $70

Updated Category News Views 242

JPMorgan Boosts W. P. Carey's Price Target Recently, JPMorgan has refreshed its price target for W. P. Carey & Co. (NYSE: WPC), raising it from $68.00 to $70.00, while retaining an Overweight rating on the stock. This adjustment comes ahead of the company’s third-quarter earnings announcement, indicating the firm's confidence in W. P. Carey’s future potential....

Continue Reading